Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2019 /
Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer

29th Mar - 3rd Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.04.19
Views: 664

Dr Constantia Pantelidou - Dana Farber Cancer Institute, Boston, USA

Dr Constantia Pantelidou speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about a study which looked at the immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer (TNBC).

She reports that PARP inhibitors induce an anti-tumour immune response in BRCA1-deficient TNBC but not in BRCA1-proficient TNBC.

Dr Pantelidou explains that this T cell recruitment is mediated through activation of the STING pathway and this activation is sufficient for the anti-tumour immune response to PARP inhibitors.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation